JMC | Insilico Medicine Publishes AI-Driven Innovative Design Strategy for Highly Selective FGFR2/3 Inhibitors (VIDEO)
Caption
For years, developing selective FGFE2/3 inhibitors has been hindered by the extreme structural similarity among FGFR family members, leading to toxicities and resistance with current therapies.
Insilico's team tackled this by combining advanced molecular modeling with its AI platform,Chemistry42, to design novel, highly selective FGFR2/3 inhibitors. These compounds spareFGFR1/4—reducing toxicity risks—and address resistance mutations, offering hope for safer, more effective treatments.
Published in theJournal of Medicinal Chemistry, this work exemplifies how AI acceleratesprecision drug discovery.
Credit
Insilico Medicine
Usage Restrictions
None
License
Original content